Clinical Trials Logo

Pancreatic Adenocarcinoma clinical trials

View clinical trials related to Pancreatic Adenocarcinoma.

Filter by:

NCT ID: NCT04143152 Active, not recruiting - Clinical trials for Pancreatic Adenocarcinoma

Pancreatic Cancer Biomarker Study

Start date: January 1, 2021
Phase:
Study type: Observational

This is a non-treatment, blood collection study to evaluate biomarker panels for the diagnosis and prognosis of pancreatic cancer.

NCT ID: NCT04137536 Active, not recruiting - Pancreatic Cancer Clinical Trials

A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer

Start date: October 17, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find the safest dose and identify any bad side effects of EGFR-BATs (bispecific antibody-armed activated T cells) for people with advanced pancreatic cancer who have already received first-line standard chemotherapy.

NCT ID: NCT04130399 Withdrawn - Pancreatic Cancer Clinical Trials

Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Start date: July 1, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to research the effects of delivering full-dose neoadjuvant multi-agent chemotherapy (folfirinox) followed by stereotactic body radiation therapy (SBRT) in patients with resectable pancreatic ductal adenocarcinoma (PDAC) in order to intensify local therapy and improve outcomes.

NCT ID: NCT04119362 Completed - Clinical trials for Pancreatic Adenocarcinoma

PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer

PARAGON
Start date: October 24, 2019
Phase:
Study type: Observational [Patient Registry]

Due to the generally poor prognosis, with no chance of long-term survival, health related quality of life is a very important objective in the treatment of patients with pancreatic cancer. The non-interventional, prospective, multicentre PARAGON study is desinged to evaluate the health-related quality of life in patients with metastatic pancreatic cancer, by analyzing the course of QoL throughout all applied therapy lines for patients with pancreatic adenocarcinoma, measured according to EORTC scoring manual and patient reported outcome.

NCT ID: NCT04098237 Recruiting - Clinical trials for Pancreatic Adenocarcinoma

Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency

PANCAX-3
Start date: December 17, 2020
Phase: Phase 2
Study type: Interventional

The objective of this study is to assess weight stability, functional changes, and quality of life when Pancreaze (pancrelipase) delayed-release 84,000-lipase units (capsules), for main meals, and 42,000-lipase units (capsules), for snacks, are added to standard of care in patients with exocrine pancreatic insufficiency due to pancreatic adenocarcinoma. This will be the first prospective study of this particular formulation in addition to standard of care in advanced pancreatic cancer patients. We will treat 40 consecutive patients with borderline resectable, locally advanced and advanced pancreatic cancer patients who present with weight loss and exocrine pancreatic insufficiency with this advanced formulation of Pancreaze.

NCT ID: NCT04077372 Terminated - Colorectal Cancer Clinical Trials

Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers

Start date: September 16, 2019
Phase: N/A
Study type: Interventional

The purpose of the study is to determine whether standardized implementation of a scripted template for discussing important issues that arise near the end of life improves the care of those who have advanced cancer.

NCT ID: NCT04060342 Terminated - Clinical trials for Non-small Cell Lung Cancer

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Start date: August 13, 2019
Phase: Phase 1
Study type: Interventional

This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of Care in Patients with Metastatic Pancreatic Adenocarcinoma followed by a Phase 2 Basket Expansion phase in Patients with Specified Metastatic Solid Tumors

NCT ID: NCT04002479 Recruiting - Pancreatic Cancer Clinical Trials

Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer

Start date: October 20, 2020
Phase: N/A
Study type: Interventional

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer.

NCT ID: NCT03983954 Active, not recruiting - Prostate Cancer Clinical Trials

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors

Start date: October 10, 2019
Phase: Phase 1
Study type: Interventional

This is a dose escalation, MTD expansion (Phase 1b) and cohort expansions (Phase 2) study to assess the safety and tolerability of a combination of NAP with durvalumab in subjects with selected advanced or metastatic solid tumors.

NCT ID: NCT03871790 Completed - Pancreatic Cancer Clinical Trials

Peptide-based Immunization for Colon- and and Pancreas-carcinoma

PICOP-GLOBAL
Start date: April 1, 2019
Phase:
Study type: Observational

An international, multicenter study to identify tumor molecular particularities and neoepitopes among participants with colorectal and pancreatic tumors undergoing surgery.